While not directly compared beyond impacts on tumor growth (Fig. 4), it is likely there are mechanistic differences between peptide therapy, which activates cytotoxic CD8 T cells to perform a broad array of immune functions, and innate-activating TLR agonists. This evidence concerns the gene CD8A and neoplasm.